HR · Healthcare Realty Trust Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HR
this stock
Healthcare Realty Trust Inc
|
$6.19B | +4.7% | -6.9% | — | 4.7% |
|
WELL
Welltower Inc.
|
$163.33B | +24.0% | +35.6% | 115.1 | 2.5% |
|
VTR
Ventas, Inc.
|
$44.42B | +9.9% | +18.5% | 160.4 | 3.9% |
|
DOC
Healthpeak Properties, Inc.
|
$14.12B | +24.2% | +4.5% | 58.5 | 3.7% |
|
OHI
Omega Healthcare Investors Inc
|
$14.02B | +4.4% | +13.2% | 16.5 | 4.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HR | -1.2% | -8.4% | +0.9% | -6.8% | +4.7% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -0.6% | -8.5% | -11.3% | -6.3% | -7.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.